Biomea Fusion (BMEA) Competitors $2.10 -0.10 (-4.55%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMEA vs. MBX, AQST, ITOS, CMPX, AVIR, TERN, ACB, SLDB, ATXS, and SLRNShould you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include MBX Biosciences (MBX), Aquestive Therapeutics (AQST), iTeos Therapeutics (ITOS), Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), Terns Pharmaceuticals (TERN), Aurora Cannabis (ACB), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry. Biomea Fusion vs. MBX Biosciences Aquestive Therapeutics iTeos Therapeutics Compass Therapeutics Atea Pharmaceuticals Terns Pharmaceuticals Aurora Cannabis Solid Biosciences Astria Therapeutics Acelyrin Biomea Fusion (NASDAQ:BMEA) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, community ranking, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment. Is BMEA or MBX more profitable? MBX Biosciences' return on equity of 0.00% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% MBX Biosciences N/A N/A N/A Do analysts prefer BMEA or MBX? Biomea Fusion currently has a consensus price target of $23.91, indicating a potential upside of 1,038.53%. MBX Biosciences has a consensus price target of $37.50, indicating a potential upside of 257.48%. Given Biomea Fusion's higher probable upside, equities analysts plainly believe Biomea Fusion is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer BMEA or MBX? Biomea Fusion received 54 more outperform votes than MBX Biosciences when rated by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 68.54% of users gave Biomea Fusion an outperform vote. CompanyUnderperformOutperformBiomea FusionOutperform Votes6168.54% Underperform Votes2831.46% MBX BiosciencesOutperform Votes7100.00% Underperform VotesNo Votes Does the media favor BMEA or MBX? In the previous week, Biomea Fusion had 4 more articles in the media than MBX Biosciences. MarketBeat recorded 5 mentions for Biomea Fusion and 1 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.24 beat Biomea Fusion's score of 1.18 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in BMEA or MBX? 96.7% of Biomea Fusion shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher earnings and valuation, BMEA or MBX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$3.84-0.55MBX BiosciencesN/AN/AN/AN/AN/A SummaryBiomea Fusion beats MBX Biosciences on 7 of the 11 factors compared between the two stocks. Get Biomea Fusion News Delivered to You Automatically Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMEA vs. The Competition Export to ExcelMetricBiomea FusionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.66M$6.89B$5.57B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.527.4422.4418.48Price / SalesN/A242.70394.09103.59Price / CashN/A65.8538.1834.62Price / Book0.446.516.774.25Net Income-$117.25M$143.21M$3.22B$248.23M7 Day Performance-8.70%1.98%1.49%0.89%1 Month Performance5.53%6.89%4.00%3.53%1 Year Performance-81.85%-2.52%16.21%5.08% Biomea Fusion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMEABiomea Fusion3.2833 of 5 stars$2.10-4.5%$23.91+1,038.5%-80.4%$82.66MN/A-0.5250News CoveragePositive NewsMBXMBX Biosciences2.4915 of 5 stars$7.64+0.3%$37.50+390.8%N/A$255.36MN/A0.0036AQSTAquestive Therapeutics1.5117 of 5 stars$2.58+2.8%$10.67+313.4%-13.1%$255.09M$57.56M-5.73160Upcoming EarningsITOSiTeos Therapeutics2.0927 of 5 stars$6.62+1.7%$25.75+289.0%-32.5%$252.84M$35M-2.1090Earnings ReportAnalyst ForecastNews CoverageCMPXCompass Therapeutics3.3847 of 5 stars$1.78+1.7%$13.38+651.4%+29.2%$246.14M$850,000.00-4.8120Analyst ForecastShort Interest ↑AVIRAtea Pharmaceuticals3.1159 of 5 stars$2.86-3.7%$6.00+109.8%-20.3%$244.60MN/A-1.3870TERNTerns Pharmaceuticals4.2642 of 5 stars$2.71+12.9%$18.38+578.0%-34.7%$236.58MN/A-2.3040Positive NewsACBAurora Cannabis0.6453 of 5 stars$4.20-5.4%N/A-49.7%$236.10M$320.81M84.021,340News CoverageSLDBSolid Biosciences3.9851 of 5 stars$3.03+18.8%$15.67+417.1%-62.7%$234.80M$8.09M-1.00100High Trading VolumeATXSAstria Therapeutics2.8114 of 5 stars$4.11+1.7%$26.60+547.2%-43.8%$231.94MN/A-1.9730Analyst ForecastNews CoveragePositive NewsSLRNAcelyrin2.995 of 5 stars$2.28+3.6%$9.60+321.1%-40.9%$230.07MN/A-0.93135Positive News Related Companies and Tools Related Companies MBX Alternatives AQST Alternatives ITOS Alternatives CMPX Alternatives AVIR Alternatives TERN Alternatives ACB Alternatives SLDB Alternatives ATXS Alternatives SLRN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMEA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BMEA Stock Free BMEA Stock Alerts